Friday, January 20, 2017

Introducing COPD Research and Practice

Dear friends we are happy to present you new Respiratory Journal: COPD Research and Practice!
http://copdrp.biomedcentral.com/
COPD Research and Practice publishes basic and clinical research and cutting edge reviews related to chronic obstructive pulmonary disease (COPD). The journal aims to facilitate discussion and dissemination of knowledge to help translate new ideas from bench to bedside by encouraging international and interdisciplinary collaboration.
Editorial from Editor in Chief Professor Mario Cazzola from the University of Rome Tor Vergata, Rome, Italy:
COPD is now the fourth leading cause of death globally, and the World Health Organization (WHO) has predicted that it will become the third most common cause of death in the world by 2030 [1]. In developed countries, current information estimates a prevalence of 8 % to 10 % among adults 40 years of age and older, whereas in developing countries, prevalence varies significantly among countries and is difficult to quote [2].
http://copdrp.biomedcentral.com/
It is estimated that more than 210 million people have the disease worldwide [3]. Concerning a large number of subjects, COPD generates important health and social costs. However, although COPD is one of the most common chronic diseases and has a high health and social impact, it is still poorly recognized among the general public and also clinicians. Consequently, there is a major and urgent need to better understand this complex disease.
Free full text:
http://copdrp.biomedcentral.com/articles/10.1186/s40749-015-0007-9

Saturday, January 14, 2017

2017 Lung Cancer Guidelines: The Eighth Edition Lung Cancer Stage Classification

Stage classification provides a nomenclature about the anatomic extent of a cancer; a consistent language provides the ability to communicate about a specific patient and about cohorts of patients in clinical studies. This paper summarizes the eighth edition of lung cancer stage classification, which is the worldwide standard as of January 1, 2017. 
http://journal.publications.chestnet.org/article.aspx?articleID=2578191

This revision is based on a large global database, a sophisticated analysis, extensive internal validation as well as multiple assessments confirming generalizability. 
http://journal.publications.chestnet.org/article.aspx?articleID=2578191

Practicing clinicians must be familiar with the stage classification system when managing contemporary patients with lung cancer.
Fulltext:

Friday, January 6, 2017

2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung

This document provides an update to the European Respiratory Society (ERS)/American Thoracic Society (ATS) technical standards for single-breath carbon monoxide uptake in the lung that was last updated in 2005. Although both DLCO (diffusing capacity) and TLCO (transfer factor) are valid terms to describe the uptake of carbon monoxide in the lung, the term DLCO is used in this document. A joint taskforce appointed by the ERS and ATS reviewed the recent literature on the measurement of DLCO and surveyed the current technical capabilities of instrumentation being manufactured around the world. The recommendations in this document represent the consensus of the taskforce members in regard to the evidence available for various aspects of DLCO measurement. 
http://erj.ersjournals.com/content/49/1/1600016
Furthermore, it reflects the expert opinion of the taskforce members on areas in which peer-reviewed evidence was either not available or was incomplete. The major changes in these technical standards relate to DLCO measurement with systems using rapidly responding gas analysers for carbon monoxide and the tracer gas, which are now the most common type of DLCO instrumentation being manufactured. Technical improvements and the increased capability afforded by these new systems permit enhanced measurement of DLCO and the opportunity to include other optional measures of lung function.
Fulltext:

Sunday, December 11, 2016

Elsevier’s CiteScore metrics provide comprehensive, transparent, current insights into journal impact

Impact plays an important part in understanding the performance of a journal over time and making decisions about its future. It is impossible to get a true picture of impact using a single metric alone, so a basket of metrics is needed to support informed decisions.
Today Elsevier is launching CiteScore metrics: a new standard that gives a more comprehensive, transparent and current view of a journal’s impact that will help you guide your journal more effectively in the future.
CiteScore metrics are part of the Scopus basket of journal metrics that includes SNIP (Source Normalized Impact per Paper), SJR (SCImago Journal Rank), citation- and document- counts and percentage cited. The integration of these metrics into Scopus provides insights into the citation impact of more than 22,220 titles.
CiteScore metrics from Scopus is a comprehensive, current and free metrics for serial titles in Scopus.

https://journalmetrics.scopus.com/?DGCID=Social_Twitter_post2&sf45681268=1

Search or filter below to find the sources of interest and see the new metrics. Report using these annual metrics and track the 2016 metrics via the links to each title’s Scopus source details page.

Be sure to use qualitative as well as the below quantitative inputs when presenting your research impact, and always use more than one metric for the quantitative part.
Use from now CiteScore metrics online:

Wednesday, December 7, 2016

New issue of Current Respiratory Medicine Reviews (Volume 12 - Number 3) online

Dear Friends was published new issue of Current Respiratory Medicine Reviews (Volume 12 - Number 3)!
http://benthamscience.com/journals/current-respiratory-medicine-reviews/#top
Table of Contents  (For viewing abstracts please visit this link)

Meet Our Editorial Board Member Pp. 183-184
Russell W. Steele
[Download PDF]
Editorial
Editorial: "COPD: More than a Moving Target!" Pp. 185-185
Alexandru Corlateanu and Joseph Varon
[Download PDF]
Review Article
Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis Pp. 186-207
Beatriz Ballester, Javier Milara, Esteban Morcillo and Julio Cortijo
[Abstract] [Purchase Article]
Review Article
Investigations of Malignant Mesothelioma Pp. 208-214
Jack A. Kastelik, Mahmoud Loubani, Gerard Avery, Anthony G. Arnold and Jaymin Morjaria
[Abstract] [Purchase Article]
Review Article
Understanding the Immune and Inflammatory Response to Rhinoviruses: Recent Advances with Relevance to Asthma Pp. 215-224
Kuhan Kunarajah, Olga Pena and John W. Upham
[Abstract] [Open Access Plus]
Research Article
Exercise-Induced Pulmonary Edema in Athletes Pp. 225-231
Serghei Covantev, Alexandru Corlateanu, Victor Botnaru and Joseph Varon
[Abstract] [Purchase Article]
Review Article
The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma Pp. 232-240
Michael Lind, Rachael Barton, Andrzej Wieczorek, Mahmoud Loubani and Jack A. Kastelik
[Abstract] [Purchase Article]
Case Studies
Pleural Involvement Due to Metastatic Melanoma: A Rare Complication and Literature Review Pp. 241-245
Misael Avalos, Salim Surani and Joseph Varon
[Abstract] [Purchase Article]

Saturday, December 3, 2016

Start a clean air revolution!

On December 2nd, Paris, Madrid, Mexico City and Athens pledged to remove diesel vehicles from their roads by 2025. This unprecedented action will have a lasting impact on improving air quality and protecting the health of residents. 
The mayors of Paris, Mexico City, Madrid and Athens say they are implementing the ban to improve air quality.
They say they will give incentives for alternative vehicle use and promote walking and cycling.
The commitments were made in Mexico at a biennial meeting of city leaders.
The use of diesel in transport has come under increasing scrutiny in recent years, as concerns about its impact on air quality have grown. The World Health Organization (WHO) says that around three million deaths every year are linked to exposure to outdoor air pollution.
The respiratory tract is the portal of entry of air pollutants, and thus the lung is the first organ affected. The range of respiratory diseases that can be caused by air pollution exposure is large. Studies on the health impacts of air pollution differentiate between acute and chronic effects. The acute effects of pollution may be apparent within hours or days of exposure, but other health effects of air pollution result from long-term exposure, leading to chronic disease.